Recently, we have shown that the inhibition or activation of the various proteins or kinases involved in mTOR pathways has been associated with neuronal survival and BBB disruption during the early stage of ischemia–reperfusion, especially within the time window of thrombolysis therapy (Chi et al., 2016a,b; Liu et al., 2018; Chi et al., 2019), which is 3–4.5 h for tPA treatment and 6 h for endovascular thrombectomy after stroke (Boulanger et al., 2018). This evidence concerns the gene PLAT and Stroke.